Skip to content

EBIT at other companies

Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
-$45.86M-10.4%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
-$128.51M+32.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%
Precigen logo
PrecigenPGEN
-$5.99M+73.5%
Zymeworks logo
ZymeworksZYME
-$47.12M-84.0%
ADMA Biologics logo
ADMA BiologicsADMA
$58.27M+67.1%

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.72B+59.2%
Enterprise value$1.76B+100.0%
P/S21.7×-25.0×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Calculated from AbCellera Biologics Inc.’s reported figures.

Plus components not separately reported this period.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s EBIT?
AbCellera Biologics Inc. (ABCL) reported EBIT of -$57.52M in Q1 2026.
How has AbCellera Biologics Inc.'s EBIT changed year-over-year?
AbCellera Biologics Inc.'s EBIT increased by 8.2% year-over-year, from -$62.66M to -$57.52M.
What is the long-term trend for AbCellera Biologics Inc.'s EBIT?
Over 3 years (2021 to 2025), AbCellera Biologics Inc.'s EBIT has grown at a 2.0% compound annual growth rate (CAGR), from $204.5M to -$217.11M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.